The fluoroquinolones are important antimicrobial agents for the effective treatment of patients afflicted with serious infections, especially when they can replace some expensive and/or toxic parenteral agents (3) . These compounds have been observed to be efficiently absorbed orally, have long serum elimination half-lives, have good tissue distributions, and have a broad range of activities against aerobic pathogens (3) . The compounds may be considered first-line agents for the treatment of complicated urinary tract infections, for some exacerbations of Pseudomonas aeruginosa respiratory tract infections in patients with cystic fibrosis, and for many osteomyelitis infections caused by gram-positive or gram-negative bacteria (3) .
However, as use of the fluoroquinolones has increased, so too has the emergence of resistant isolates (3, 4) . This resistance pattern has generally been most prevalent among staphylococci, acinetobacters, and P. aeruginosa isolates. Cross-resistance among the fluoroquinolones appeared common, likely because of mutations in their target proteins (DNA gyrase) and/or decreased drug permeation into the bacterial cell (3) . This increase in resistance to the fluoroquinolone drugs emphasizes the importance of the continued development of new structural candidates.
CS-940 is a novel trifluorinated quinolone ( Fig. 1 ) in the initial phases of investigation (2, 10, 11) . In addition to the 6-fluorine generally found on currently available quinolones (3), CS-940 contains a difluormethoxy group at the 8 position (10) . In animals, the pharmacokinetic behavior of CS-940 was similar to those of current therapeutic fluoroquinolones, with acceptable oral absorption (Ͼ80%), a plasma elimination halflife of 2.6 to 7.5 h (species dependent), and good distribution to the liver, kidneys, and lungs (2) . Initial susceptibility studies have documented that CS-940 has a broad antimicrobial spectrum in vitro and in vivo, with potential effectiveness against some ciprofloxacin-resistant Staphylococcus aureus strains (10, 11) .
In the present study, the in vitro antimicrobial activity of CS-940 was tested by broth microdilution and agar dilution methods against 751 clinical isolates (see Tables 1 and 2 for details about the species) collected at the University of Iowa Hospitals and Clinics (Iowa City, Iowa) since 1993. These results were compared with those for three investigational or clinically available fluoroquinolones (ciprofloxacin, ofloxacin, clinafloxacin) as well as two broad-spectrum parenteral ␤-lactam antimicrobial agents (cefotaxime, piperacillin-tazobactam).
Ciprofloxacin and cefotaxime were purchased from Sigma Chemical Co. Lederle Laboratories (Wayne, N.J.), and CS-940 by Sankyo Co., Ltd. (Tokyo, Japan). Prepared Media Microbiologic, Inc. (Tualatin, Oreg.), produced and ensured the quality of the microdilution trays containing the drugs diluted in cation-adjusted Mueller-Hinton broth. The trays were stored at Յ60ЊC until used. Broth microdilution assays were performed according to the recommendations of the National Committee for Clinical Laboratory Standards (NCCLS) (7) . Fastidious organisms were tested by the agar dilution method with medium modifications (Haemophilus test medium, blood-supplemented Mueller-Hinton, brucella blood agar) and the procedures outlined by NCCLS (7) (8) (9) . The test results were interpreted by NCCLS criteria (9) or those recently proposed in peer-reviewed publications (5) . Table 1 contains the antimicrobial activity results for CS-940 and the five comparison drugs tested against 239 gram-positive bacteria. Among the Enterococcus spp., CS-940 (MICs at which 90% of isolates tested are inhibited [MIC 90 s], 1 to 4 g/ml) was slightly more effective than ciprofloxacin and ofloxacin, but it was less potent than clinafloxacin, especially against Enterococcus faecium. Likewise, for the oxacillin-resistant S. aureus isolates, CS-940 was more active than ofloxacin or ciprofloxacin. The oxacillin-susceptible strains were highly susceptible (MICs, Յ 0.12 g/ml) to CS-940. Staphylococcus haemolyticus, Staphylococcus epidermidis, and the additional coagulase-negative Staphylococcus spp. tested (see Table 1 , footnote d) were generally less susceptible to these drugs, and the rank order of potency was clinafloxacin Ͼ CS-940 Ͼ ciprofloxacin ϭ ofloxacin. CS-940 was two-to fourfold more potent than ciprofloxacin and ofloxacin against Streptococcus groups A, B, C, and G. CS-940 (MIC 90 , 0.25 g/ml) was markedly more potent than the other fluoroquinolones tested (MIC 90 s, 2 g/ml) for the Streptococcus pneumoniae strains tested. All pneumococcal strains resistant to ciprofloxacin or ofloxacin were susceptible to CS-940 (MICs, 0.25 g/ml). Two strains of Listeria monocytogenes were also inhibited by CS-940 (MICs, Յ 2 g/ml; data not shown).
The results for CS-940 antimicrobial activity against 520 gram-negative organisms are listed in Table 2 . A limited number of fluoroquinolone-resistant members of the family Enterobacteriaceae (four strains of Providencia rettgeri and two strains of Serratia marcescens) were tested, thus affording a true comparison of potency (MIC only) and not cross-susceptibility or cross-resistance. The activity of CS-940 against Citrobacter freundii and Enterobacter spp. (many of which were resistant to the beta-lactams tested) was similar to those of ofloxacin and ciprofloxacin (MIC 90 s, Յ 0.5 g/ml). Among the other enteric organisms, CS-940 was most active against Citrobacter koseri, Escherichia coli, Salmonella enteritidis, and Shigella spp., for which MIC 90 s were Յ0.03 g/ml. Clinafloxacin and CS-940 were the most active compounds tested against Acinetobacter spp. (MIC 90 s, 0.03 g/ml) and Stenotrophomonas (Xanthomonas) maltophilia (MIC 90 s, Յ2 g/ml). This potency was four-to eightfold greater than that of ciprofloxacin or ofloxacin. CS-940 also demonstrated good activity against fastidious species such as Haemophilus influenzae, Moraxella catarrhalis, and Neisseria gonorrhoeae (MIC 90 s, Յ0.06 g/ml), with activity nearly identical to that of ciprofloxacin.
All aerobic gram-negative organisms were susceptible to CS-940 with the exception of a few strains of P. rettgeri, S. marcescens, P. aeruginosa, S. maltophilia, and several strains of infrequently isolated gram-negative organisms. There was a large degree of fluoroquinolone cross-resistance among these organisms, but clinafloxacin generally remained the most active compound (data not shown).
Anaerobic species such as those in the Bacteroides fragilis group (MIC 90 , 2 g/ml), Prevotella spp. (MIC 90 , 8 g/ml), Clostridium spp. (MIC 90 , 1 g/ml), and peptostreptococci (MIC 90 , 2 g/ml) were consistently more susceptible to CS-940 (50 to 100% at MICs of Յ2 g/ml) than to ciprofloxacin.
CS-940 is a novel trifluorinated quinolone (2, 10, 11) that was evaluated against 761 clinical isolates. CS-940 exhibited an a Susceptible according to NCCLS. The criteria used for CS-940 were those indicated for ofloxacin supported by preliminary pharmacokinetics (2). The criteria used for clinafloxacin were the same as those used for ciprofloxacin (4) . Oxacillin-resistant staphylococcal strains susceptibility criteria for beta-lactams follow the recommendations of NCCLS found in document M7-A3 (6) .
b The percent susceptible data for CS-940 and clinafloxacin are given in parentheses to indicate tentative interpretative criteria. antimicrobial spectrum that generally was equal to or slightly superior to those of ofloxacin and ciprofloxacin. These results suggest that CS-940 may have the potential for use against some ciprofloxacin-resistant strains, particularly among anaerobic organisms, S. pneumoniae, and staphylococci. The present investigation also indicates that further studies should be initiated to characterize the pharmacokinetic and toxicologic properties of CS-940 in humans. 
